Q2 2020 Oncolytics Biotech Inc Earnings Call
Hi.
Gotcha.
Good day, everyone and welcome to <unk>.
Next I will take second quarter 2020 earnings conference call.
Just being recorded.
Reminder, today, Please press star one to ask a question.
I like to turn the conference over to talk a lot of lifestyle advisors. Please go ahead Sir.
Thank you operator, good afternoon, everyone and welcome to all public biotech second quarter 2020 conference call.
Earlier today.
Culturally, it's providing their financial results.
The second quarter <unk>.
A replay of todays call will be available Investor Relations section Alcoholics, one site approximately two hours after completion.
Marshall.
We will open the call for Q.
A reminder, birthmarks made during this call about the company's future expectations plans and prospects.
Constitute forward looking statements for purposes of the Safe Harbor.
I'm going to private Securities Litigation Reform Act with my journey.
Actual results may differ materially for those indicated by these forward looking statements.
Embarrass important factors, including those discussed no risk factor section of the companies.
For a form 20-F.
Yes, you see the district any forward looking statements represent the company's views only as of today, but you're not hear a lot upon as representing their view any subsequent date.
As required by law uncle, it specifically disclaims any obligation to update or revise any forward looking statements either the company the news change.
I will try to go over to Dr., Mcafee, President and Chief Executive Officer.
No.
Thanks.
Thanks to all looks like for joining us on its called stayed to discuss our second quarter corporate update.
In addition to Tom I'm joined by Andrew Do you got it though global head of business development Crinkle cut Chief Financial Officer.
Yes, I forget what they call I'd like to say, how incredibly proud of all the members adult subjects to their talents and unwavering dedication because a lot of snake truly remarkable progress over the last quarter.
She clearly laid the unpredictable industry wide challenges posed by the cold it batching sometime it.
They do especially people chasing me a little parts business continuity plan, all could actually be able to achieve slide clinical milestones, including treat data read outs in the second quarter.
The placement as well so I'll just go get important.
Hi, clinical validation with our unique okay bias immunotherapy platform, while also advancing our big breast cancer program towards initiation of a Registrational study.
Looking forward, we are well positioned to continue recording a steady cadence of value, creating milestones across our diverse clinical pipeline.
I'd like to bought a good watch a little bit highlights from a productive quarter.
We remain focused on the critical about sort of color arc intravenously delivered.
Click buyers.
It's a registrational study in HR, Togneri hertwo negative metastatic breast cancer.
That's substantial unmet need exists in this indication. That's currently approved therapies are able to produce meaningful survival data.
So the over 112000 patients with the diseases in upstate slope.
To address that something that wage.
We continue to build up the results of our phase two study R&D to 30 metastatic breast cancer trial that showed a near doubling of overall survival, telling your up treatment in HR pause it approaching negative patients.
Courage by this data we're conducting are aware one in place to clinical study the completion of which journey the design never Peachtree Registrational program.
Together these ongoing studies aim to achieve three objectives to facilitate the initiation of a phase three trial.
First the either confirm coloring reps and you got therapeutic mechanism of action to support the promising efficacy data generated by Ari Beachy 13.
Second the its ability to clinical utility other double blood based biomarker nitrate T cell quite a hobby predicts the patient response to Colombia.
And finally, they will evaluate telomere ups ability to it helps the topic of seats, a checkpoint inhibitors to improve patient outcomes as there's a robust preclinical and clinical dataset supported this synergistic potential telegram rep checkpoint inhibitor combination therapies.
And represents the first you said a clinical supply pregnant with Roche.
Following a recent expansion in the number of aware one trial sites. We are rapidly in your own for you since in the study thanks to a double you know the number of study centers.
<unk> tried to the spam reopening.
Awesome.
Thank the last week successful Safety Committee review, we once again verified teller rewrites outstanding safety profile.
It's progress has been further bolstered by positive data generated such as the recently announced compelling data presented at the 2020 as my breast cancer meeting.
[noise] with also highlighted in a recent K T opinion later caller K O L call featuring Doctor, Alex Pratt Chair of Solti, Emma Lee translational investigator of where one.
Garry with K O L call Doctor Pratt spoke to how old are you aware one data confirmed college reps, let me know therapeutic mechanism of action.
Support the critical utility of tea chocolate ality as a predictive M prognostic biomarker.
And demonstrated <unk> potential to synergistically combine the checkpoint theaters across multiple breast cancer subtypes.
Specifically the data show that systemic teller order off the administration was followed by tumor specific replication, which led to the creation.
And mobilization, a tumor targeting C D cause the T cell phones and increased tumor P. D O one expression.
Notably.
<unk> also show that teller, a rough treatment leads to an increase in <unk> <unk>.
A measure of two more information and the studies primary complaint.
Such date is particularly exciting when considering that patience with high self-help scores have improved clinical outcomes.
<unk> increase in social also correlated with peripheral cheese hook finality supported to you. So the biomarker, which may allow us to select stratified patience, we're more likely to respond to treatment and a pivotal studies.
Taken together previously reported results from aware one.
They demonstrate the substantial progress made towards achieving a critical objectives necessary to move our lead breast cancer program into a registrational studies.
Looking ahead, we expect the Bachelor this trial to continue and Ernest.
Highly encouraged by this progress and we'll keep you up to date of the Taliban ounces.
Maybe no now to brace with one or face to trial evaluating the safety and efficacy Peloria Rutgers combination therapies D. H R positive her to negative metastatic breast cancer patients.
Like in aware one the exceptional work with y'all quit it's T N and it's partners throughout the midst of this <unk> debit card the lettuce with cheese critical smell. So I'm Gonna study as we recently those are first patient following the opening at the first two sites in the study.
Do you expect to see an acceleration the opening a additional sides over the next corner that's hospitals adapter the running studies in Cogan 19 pandemic environment.
As a reminder, bracelets design was developing collaboration what size room or K G. A N as essentially a debit card for the study design of a prior I N D. T 13th study what two exceptions.
Personally the study focuses exclusively on H R positive Hershey like the subset submit a side of breast cancer patients, which is the patient population in which we saw the pronounce over all survivor benefits P. M. I N D T 13th.
Second.
He's going to add an additional study arms without a television in combination with fries room or to N. P. P. D O one chocolate and sugar does M C O.
As I mentioned earlier. This design was developed to support the overall survivor advantage observed in 90 213 by demonstrating telling me up the ability to induce a robust antitumor immune response.
And a denticle patient population <unk>.
Additionally, the study aims to validate cheese, all carnality utility as a clinical biomarker and evaluate the efficacy of telling me about checks appointment to get it a combination therapy.
Fortunately.
We believe that are aware one in bracelet studies present multiple opportunities for value infection points in the near future.
Check like give them, how prior data and regulatory interactions D where to start over all breast cancer program.
As those who had been follow what else for some time May I know you previously received favorable feedback from the F. D. A N F as to meeting.
<unk> E M. A final advice letter.
Faster designation and a special protocol agreement for a metastatic breast cancer program.
These regulatory achievements combined with our progress Embracement one in a compelling aware of data showing that we are on tried to make the clinical objectives needed to initiate a registration study demonstrate how the hard work of our employees partners T shirts, and investigators Ah D list or leave clinical program instead of bronchitis for near an longterm success.
Yeah, I'd like to sit there is a bit and talk briefly about the recently and out expansion of our breast cancer program into new disease subtype triple negative breast cancer.
About a month ago, we announced R. New Irene study, which is the faith to investigators sponsored clinical trials designed to evaluate Colorado rabbit in combination with insight anti P. D. One chocolate and pepper Red a family mouth.
It is childhood answered dress a critical unmet medical need is there are over 460000 triple negative breast cancer patients and the U S alone.
Importantly will checkpoint inhibitor therapy, the proof of the treatment a triple negative breast cancer.
Forget limitations.
Only about half a triple negative breast cancer patients have the one per cent P. D O one expression levels needed to become eligible for checkpoint therapy at this time.
Those 40 per cent are likely to respond to treatment.
This represents a very interesting clinical and market opportunity for <unk>, which is highlighted by the aware one data show it in the ability to increase in to repeat L. One expression <unk> treatment across multiple best Kansas I'd types.
Tuesday to highlight telegraphs potential to increase the number of patients that are eligible for and can respond to checkpoint hamburgers, thereby helping to address is pressing unmet need a triple negative breast cancer.
Moving on and I'd like to ship the discussion away from her primary so it could submit a side of breast cancer and towards the polka tomato hematological in castle and personal transfer indications.
These programs demonstrate both the depth of our Python in the broad commercial opportunity offered by telling them to erupt continue the bathroom.
I also do a cheese in each of these programs and the second quarter, a new clinical data from trials evaluating teller, we were up in multiple myeloma and pancreatic adenocarcinoma, what presented as part of the Apsell medium helping me.
We saw some south of any proof of concept multiple myeloma, which is an indication where the incredibly and you know suppressor made sure that the cancer microenvironment has prevented the success the checkbook and peppers.
When patients that are multiple myeloma trial were treated with <unk> in combination with a proteasome inhibitor propel us.
We saw the activation all of a profound inflammatory response, accompanied by 50 per cent overall response rates and 83 per cent clinical benefit right.
These resolved to include the first reported incidents cytokine relief syndrome associated with clinical responds with multiple myeloma.
The induction a side of kind of late syndrome, which can be a secondary manage with well-established therapies highlights the ability to tell him Rover propeller combination treatment to induce robust onions, I'd like to nation and tumor license and most of my Loma patients.
Because telling data seem here are even more noteworthy when considering that to trial was carried out and <unk> refractory patients who are notoriously difficult to treat.
Importantly, when this recently announced need are considered together with cream is that you reported trials is all showing a dramatic increase the P. P O one expression with teller wherever treatment, we strongly suppose the success of our ongoing clinical study evaluating teller grilled <unk> grilled cheese, and Ham and an immune checkpoint inhibitor therapy in multiple myeloma.
Finally.
Right hand off the call to Andrew to elaborate on or P. D athletes I'd like to give a brief update on a work and J I cancers.
As in breast cancer, multiple myeloma weird compelling clinical data from my gerbil leniency, demonstrating teller potential to synergistically increase the effectiveness with a medium chocolate inhibitors.
This includes date of recently presented at ask them from a trial evaluating teller, where keytruda combination therapy and the second one pancreatic cancer patients.
These data show that the therapy as well tolerated and resulted in tumor specific replication high degree cheats all repertoire trying to increase of a new T cell phones are a peripheral blooded these patients.
Looking ahead. These recently reported resolve add to it as a robust set a clinical data <unk> ability to cry medium system across several types of July cancers.
Notably the state is stopped driving sound very interesting discussions around potential industry and academic collaborations.
That may complement our existing relationships quite nicely.
Now so let you hear some more of these more about these excited cloudberry something other I'm going be D. S. It's I'll have to call over to Andrew.
Thanks, Matt.
Cause we mentioned in the past, there's a growing interest from large format in biotech companies improving the episode Cecconi Hamburgers Library <unk>.
This has been marked by several meals that companies such as Mark M. S. N. J&J would you have typically been procedure by neutral cooperation designed to valued the feasibility potential combinations.
Exactly <unk> chocolate lettuce, just taking a ongoing telling me a rep studies design to valuation central synergies approaches center.
Five zero Mercury G H a N G L.
P M S as in an email and now insides rent a family man.
The way, which we have been able to gain such or something like mystery collaborations has been by damaging a robust clinical data is that.
Exciting Margaret opportunities presented by the clinical area has been <unk>.
One recent example, and successful can execute from the strategy is where do you read study my disgust earlier.
A strawberry on and off the ability to increase to repeat your on one level is precisely sweet withdrawal initiation of this investigator sponsored trial.
[noise] collaboration along with their Awesome code development agreement with Fries with no K J E placement, one study or just two examples of power effectively leveraging Arkansas and clinical data.
Initiate imposter relationships a dog farming biotech.
Also important enough that the commercial opportunity abusing power Bureau, some fruit chocolate and sugars expand beyond just breast cancer.
As a whole the chocolate and I'm gonna Mark It as a chocolate reached 25 billion by 2022.
Even though nothing one five patients respond to these therapies.
Further next H like salary minute span grown.
I'm going to come with companies Must've looked for sake, and efficacious ways to further expanded potential indications.
Oh, you're what is extensive synergy data and the ability to be administered intravenously.
Represents an exciting opportunity to visa.
It's not discussed earlier number bus clinical dataset, demonstrating telling me all extra attention to increase the percentage of pensions responding to chocolate and sugars.
Not surprisingly, we find out the bed, if you'd just suddenly dog exciting business, the mountain and opportunities across her python.
For example, what currently want me B M. S. N a problem. Some study about it we are lucky the combination therapy multiple myeloma patients.
Looking forward Ah garlic secure global plenty Punkah Marsha commercialization partnership.
Both facilitate <unk> approval and maximizes commercial opportunity.
We spent forthcoming clinical data particular embrace I'm in a real one two drivers towards the salt I Gotcha, I'm gonna discussions with potential partners across the phone the biotech industries.
With that I'll turn to call over Coke luck are CFO to discuss our financial resolved an appointment first.
Thank you Andrew Yeah, good afternoon, everyone.
But it seems to report that answer that for names sound financial position is <unk> towards registration.
Her balance she continues to remain strong with cash in cash it goes with $29.9 million at the end of the second quarter.
This include sniff proceeds to 6.4 million for at the market facility, which was recently removed and importantly extends her furniture only to the end of 2021.
The research and development expenses for the second quarter of 2020 with $2.5 million compared to $3.4 million for the same period last year.
These activities such a gun progressing are aware and bracelet studies.
Supporting other checkpoint inhibitor combination trials and securing a clinical supply will just started C. G M P production room.
Alrighty, So just for the second order, a $3 million compared to $1.8 million and 2019.
During this period the increase in or operating expenses related primarily to increase my investor Relations and business development activities as long as an increase in or directors, an officer insurance premiums.
Finally, ornette lost for the second quarter was $628 million compared to 5.3 million last year.
Waiting to a lost for sure of 17 cents for the quarter versus 26 cents for the quarter.
2019.
With that I'll have it back to milk.
S.
Sure.
It.
First.
I want everything.
Different.
[noise] Barcoded viruses, which is Andrew mentioned is Mary upgrade interests large farner.
Almost all other unquoted viruses development.
Either have at least one and often both of these two characteristics.
Do you require special handling procedures or the bsl's reclassification or they require <unk> mail delivery and therefore cannot reach metastatic disease.
Notably Peloria Rep is administered systemically by nursing staff requires no special handling procedures has been clinically demonstrated to selectively replicated in local and metastatic tumors.
These characteristics offer auklet substantial competitive advantages over other I'll go to borrow companies.
Further Colorado for me the only viable agent to show a survival benefit benefit and late stage metastatic breast cancer and it's supported by data from multiple clinical studies, demonstrating as potential to order a check point inhibitor therapy.
Looking ahead, we expect to build valued through the sustained progression of are clinical programs and continued development of our industry partnerships.
We believe we're well on her way to a day I was gonna leave H O positive her treating me metastatic breast cancer program into a Registrational study and we continue to work diligently with our academic an industry collaborators to broaden your commercial opportunities in Hematological a G. I Boynton. Please.
There, we expect the future of the pandemic to presents challenges across the biotech Department industries, the extraordinary dedication and talented sprayed by our employees and partners over the last several months basic confident that will continue to build on the positive momentum generated last quarter.
This will allow us to cassini generating value for our shareholders at most importantly put the lives cancer patients.
Does that I would like to open the lines and take some questions operator.
Oh. Thank you so hard to ask a question at this time I forgot to say my nephew my preference Taiwan on your telephone keypad, that's kind of you from my Speaker phone today. Please make sure you me how can I just turned off Tonight signal to reach us once again that style mine to ask a question.
What passes to paint on it.
Okay can I first question cause I'm trying to finish off with Ross Cat partners.
Thank you very much. So the lines are it's going to do so I hope you can hear me he hasn't been of a storm over here.
But I wrote it over the past sick, Yes, you don't believe you over the past six months or so.
About moving into G I cancer, and I think I heard you extremely greasewood.
<unk> My T bedroom elaborate.
<unk>.
Yeah, No L N. There's been a very busy in this regard we.
Are working on various protocols now what we're what we're contemplating and hopefully in the context of an industry partner it will be G. I N. A basket study if you will we've seen positive results in colorectal we've just published those results.
M D. M C. I published a positive study and pancreatic cancer pre selected Ah patients with secam sick expression. So we were very much believe it's an area that we should be pursuing.
We do have a number of industry partners that recording for this the protocols are nearly completed so I I think it's just a question of execution and hopefully that'll be.
2020th and obviously everybody's stuck working from home. So it's hard to get committee approvals, but after you've done a phenomenal job a movie me is [noise] <unk>.
Initiatives ahead for us I mean, it's something we hope to be able to announce second half of the year.
Okay. There's a second questions a couple of friends and so just kind of bearing with me but.
When was the C. A critical Nancy thing, England.
Mm Hmm breast cancer, and I guess correct me from them numbers, but since you will be 2017.
And you read it out I N D 213 that was about 77 nations and then I'm I believe you said, what we've seen from them as <unk>. Since then has just been without it doesn't are so patient the first oven and somebody from.
And so when I say critical mass smells like when do you have a critical mass patients and breast cancer, you some minor breast cancer onion enough data.
So that you can construct a pivotal tryin' it'll contain and one day or anything like between two ones.
So that you can see the contribution could come with.
[noise]. It was a great question and I just want it comes up all the time 77, <unk> and you you know the study in terms of being basketball Adret very clear you know obviously people are looking for a larger M. But we were I I think there was people you know looking at the results in Saint well, that's a sad.
How to put the protocol was really Brittany b.
A side of dogs I can now you're seeing those you know delayed clinical benefit you're sitting on proportionality, that's very clear I could doesn't immunotherapy and unfortunately to 13 didn't capture that's I mean, a therapy data <unk>.
What we're getting from aware I think there's some of the most compelling data that demonstrates nearly definitively what's happening in the size of the level and it it because there's paired biopsies between the initiation the study and the final Miss that to me, we can buy looking in the tumor microclimate in the peripheral blue.
We can tell them very complete story of Y 213 wasn't success, how old immune system was engaged with the order. The engagement was with a relative contribution I'm not sure I'll kill ourselves versus the cheese off of our we Unfortunately, you know our our living in the middle of a pandemic. So the the <unk>. The aware study was cause.
For three months, we use that time to double the number of centers that group is very excited about the study going forward.
We did have a T O L call, where the investigator was talking about the future of the agents I think you're aware one gives us the complete study and right now we just we just finished the safety evaluation with the the D. S. M. B they found out concerned with it. So now we can enroll the remainder of the study always when you started these studies or is a bit of a risk because we were giving.
Chocolate inhibitor too to women's out of fully functional immune system. So we wanted to proceed slowly to make sure that we weren't putting anybody at risk, but frankly, you do the safety profile looks exceedingly good the investigators there have submitted abstracts to sit C as well as San Antonio Breast conference. So to my mind in terms of a complete picture of the biochemistry and with a <unk>.
Roll that the checkpoint inhibitor will be presented that San Antonio Press conference. The final prefer the final nail on the coffee if you will as the bracelet study or <unk>.
Oh, and rolling I'm, hoping that it gives us a very clear indication or the relative contribution of the chocolate inhibitor in the metastatic setting, but biochemistries biochemistry, if we see a decrease.
In the threshold that we need to get to improve sell Taylor improved inflammation in person. So the checkpoint debit or I think we can start planning that cheese, three well before very fluffy and finish though to my mind complete biochemistry picture you know in what is the 36 patients with aware one I think compliments everything the 70, you know some odd patients I wasn't willing to 13.
And then whether or not pharma needs that last bit of data coming from bracelet will be seen but it's likely round in my study that that shows it so to my mind I think we're done with aware, one naysayers, where people who are sitting on the French I think I'm gonna wait for the bracelet results, which you know that so you should be finish all that next summer with final data getting probably being cause I'm does that sound right.
On your Best Conference 2021.
In any case, though you know we've made some critical hire some more planning for the food three now so that we can do gap analysis to make sure. That's in the context of a farmer partner that we can code development that they can look at us on a clinical payments. Yes. This is a critical partner or this is a critical group of people that can run the partnerships up there contemplating.
Okay and the the former C M. What what was the country you know what caused that.
Yeah.
You know typically the type of disclosure as we can say someone work. There then they didn't <unk>, we brought on Doctor Tom vitamin He's got a background and infectious disease, an apology. He's that's a fantastic higher for us I'd actually has been working too already integrated approved a clinical team over the last several weeks so I.
Look to them, but we really don't discuss why people leave organizations.
Okay, and and the last the last little two part of it was just was there anything T M. Since June 30th and what we named either way on the 19th.
Ah Creutzfeldt zero barely work I'll, let you answer that one.
Yeah, we've used it in July.
A million dollars vanilla D P M push renewal.
Okay, and what and what the names on it.
That'll be third easily.
Okay. Thank you very much thanks for taking all the questions that childhood.
Just a reminder to your audience, Taiwan do you have a question are common at this time is sterling.
Next to John Human with 10 o'clock.
Hi, guys. Thanks for checking the question.
Noon.
Question was on the branches study I'm just curious if you can talk to a specifically about what are you looking for in terms of peaceful tonality.
Just wondering if you could talk about you know in the past for example, when the P. D wanted hamburgers or first thing developed why people weren't able to look at that at the local a detailed up here now thanks.
Okay Great question.
Shot and time of what your T cells were doing and to tell her a great way of.
Demonstrating that you've had to vaccination effects everyone. Now is very focused on vaccines and what have you and these things like two chocolate ality could actually died patients like you can look for an antibody responds where you can look for a cheese held responsible what's what essentially what we're looking for is and it's a three or I'm, sorry, so with a paclitaxel.
<unk> to toxic stone increased two chocolate holiday so our our our expectation is with those patients.
Seem to Paclitaxel will look at your baseline in three weeks later, and we really don't anticipate there it'll be much of a change in the composition or constitutional or the cheese I'll respond.
If we see it back successful vaccination effects and we draw the natural colors I'll put a tumor and we got licensed what we expect to see is the generation a brand new T telephones, and if anyone's ever seen or plot.
What happens is that baseline you don't have these fees, Oklahoma and post treatment. What we're looking for the generation 234 hundred unique novel clones that are are likely to wreck central tumor out the token viral epitope and those are typically on the vertical access of our appointments o'clock and really all that telling US is yeah. This guy who's now have the onions.
Some exposed to viral epitope, a tumor epitope and you know they've had this very positive response now <unk>.
<unk> inhibitors other than C. T L. A for which we haven't worked with politically don't generating T. Telecom. So they don't cry and the immune system. So we should be able to cheese out with the virus was doing very nicely from what the checkpoint hamburgers doing so give me arm or would you be paclitaxel plus virus, what we're gonna be looking for is on that vertical access the generation a brand new teeth, Oklahoma.
Now this can be further augmented.
By check went blockade.
Checkpoint blockade as I said doesn't generate new pizza, Oklahoma, but it does do a pretty good job of activated no cheese, all that existed at baseline and that's at Middle field that we talk about it would be about it and see plot, where there's maybe 15 20 call them that did recognize the tumor but through the business leaves in through treatment. They do it becomes so <unk>.
So that they just kept target disease anymore. So when the arm or we add the prevents you know what we're hoping to see it would be great enhancement of that middle field in combination with the killer I used to have no cheese, how calls now again with it where one we can measure tumor microenvironment. So we can look at activation markers onto your telephones.
We can characterize what immune solves are there.
And finally results from our animal studies and now what we're starting to see in humans. When we treat with three of our S. We got a big increase in Clamatorial salt, but we did a slight diminishment of anti-inflammatory salt sounds like T. Regs sounds like a N D. S C, but we presented a pole.
Started in collaboration with Tomatoes on them when we added a checkpoint and hamburger that combination what we find is within the tumor and wife environment anti-inflammatory sell these T. Ragged does M. B a C. R. A lemonade it from the tumor my friend apartment. So we're one visit her very complete picture.
Which inflammatory so I'll go there, which solves are not there in the combination what sells are activated which ones that are still basically suppressed from working so we got a very accurate depiction and that points us to like very obviously you wanted to have an elimination inflammatory. So early results are suggesting that that's what happens.
Through the activity to check what inhibitor. So we'll have a much more complete picture of that and that'll be presented so I know that.
They have submitted to San Antonio They are planning I'm submitting to <unk> and we should have sufficient data now that spans opened up they've been able to ship all the samples out. So we're doing imaging mouse specs for doing cheese, all <unk> all of a side of card responsive measuring the gym response, a recent publication, we had demonstrated that rid of ours treatment and <unk>.
Combination what side of Toxics, we would actually see a genetic changes we'd see overexpression Pro-inflammatory jeans. These were express is markers as well salary of changes and finally it was all put in clinical changes. So we're hoping to be able to have that sorta full accountability from the aware one study as well with it as well as what we get into the <unk>.
Sorry.
Okay, great. Thank you.
Once again just to remind her try and star one if you have a question are coming at this time that star one what possibly funny.
[noise].
[noise] [noise] [noise] [noise] [noise] [noise] [noise] [noise].
That's all the time, we have for questions at this time, everyone I'm trying to call back over to our speakers for any final or Additionally, Max.
Thank you operator, I appreciate that and listen thanks, everyone for taking the time to listen to these calls I. Appreciate it is earning season was very busy.
[noise] [noise] that I just wanted to thank everyone for their time and I wanted to take all the stuff in on quite it's for all the hard work and all the collaboration with all the industry participation and the patients and their families participating in the studies, thanks very much better.
You're quite welcome that does conclude our conference call for today anyway. Thank you all for your participation you may not disconnect.
[music].